Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: An update on issues to consider

Oncologist

Volumn 15, Issue 11, 2010, Pages 1169-1178

  Tsoutsou, Pelagia G ^a   Belkacemi, Yazid ^b   Gligorov, Joseph ^c   Kuten, Abraham ^d   Boussen, Hamouda ^e   Bese, Nuran ^f   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d RAMBAM MEDICAL CENTER   (Israel)

^e ABDERRAHMAN MAMI HOSPITAL   (Tunisia)

^f ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Arome; Breast cancer; Chemotherapy; Delay; Hormone therapy; Radiotherapy; Sequence; Trastuzumab

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; LEUKOPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NITRILES; QUALITY OF LIFE; RADIOTHERAPY; TRIAZOLES;

EID: 78649964387     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0187     Document Type: Article

References (97)

1. Berry DA, Cronin KA, Plevritis SK et al. Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy. N Engl J Med 2005;353:1784-1792.
2. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32.
3. Balduzzi A, Leonardi MC, Cardillo A et al. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. Cancer Treat Rev 2010;36:443-450.
4. Adamowicz K, Marczewska M, Jassem J. Combining systemic therapies with radiation in breast cancer. Cancer Treat Rev 2009;35:409-416.
5. Tsoutsou PG, Koukourakis MI, Azria D et al. Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. Crit Rev Oncol Hematol 2009;71:102-116.
6. Hébert-Croteau N, Freeman CR, Latreille J et al. A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. Breast Cancer Res Treat 2004;88:187-196.
7. Ruo Redda MG, Verna R, Guarneri A,et al. Timingof radiotherapyinbreast cancer conserving treatment. Cancer Treat Rev 2002;28:5-10.
8. Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment affect the outcomes ofradiotherapy? A systematic review. JClin Oncol 2003; 21:555-563.
9. Bese NS, Munshi A, Budrukkar A et al. Breast Health Global Initiative Radiation Therapy Focus Group. Breast radiation therapy guideline implementation in low- and middle-income countries. Cancer 2008;113(8 Suppl):2305-2314.
10. Punglia RS, Saito AM, Neville BA, et al. Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. BMJ 2010;340:c845.
11. Wyatt RM, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol 2008;81:549-563.
12. Dunn BK, Agurs-Collins T, Browne D et al. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 2010; 121:281-292.
13. Benk V, Levinton C, Fortin PR et al. Effect of delay in initiating radiotherapy for patients with early stage breast cancer: results of a natural experiment. Int J Radiat Oncol Biol Phys 1999;45:305-306.
14. Clarke M, Collins R, Darby S et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-20106.
15. Vujovic O, Yu E, Cherian A, et al. Eleven-year follow-up resultsinthe delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys 2006;64:760-764.
16. Nixon AJ, Recht A, Neuberg D et al. The relation between the surgery-radiotherapy interval and treatment outcome in patients treated with breast-conserving surgery and radiation therapy without systemic therapy. Int J Radiat Oncol Biol Phys 1994;30:17-21.
17. Slotman BJ, Meyer OW, Njo KH et al. Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer. Radiother Oncol 1994;30:206-212.
18. Hershman DL, Wang X, McBride R et al. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 2006;65:1353-1360.
19. Livi L, Borghesi S, Saieva C et al. Radiotherapy timing in 4,820 patients with breast cancer: university of florence experience. Int J Radiat Oncol Biol Phys 2009;73:365-369.
20. Olivotto IA, Lesperance ML, Truong PT et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol 2009;27:16-23.
21. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356-1361.
22. Kaufmann M, Morrow M, von Minckwitz G, et al. Biedenkopf Expert Panel Members. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010;116: 1184-1191.
23. Goldhirsch A, Ingle JN, Gelber RD et al. Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319- 1329.
24. Goldhirsch A, Glick JH, Gelber RD et al. Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
25. Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane Database Syst Rev 2006; 4:CD005212.
26. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
28. Hartsell WF, Recine DC, Griem DM et al. Delaying the initiation of intact breast irradiation for patients with lymph node positive breast cancer increases the risk of local recurrence. Cancer 1995;76:2497-2503.
29. Buchholz TA, Austin-Seymour MM, Moe RE et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993;26:23-35.
30. Recht A, Come SE, Gelman RS et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol 1991;9:1662-1667.
31. Leonard CE, Wood ME, Zhen B et al. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol 1995;13:2906-2915.
32. Meek AG, Park TL, Weiss TA et al. Effect of delayed radiation therapy on local control in breast conservation therapy. Radiology 1996;200:615-619.
33. Yock I, Taghian AG, Kachnic LA et al. The effect of delaying radiation therapy for systemic chemotherapy on local-regional control in breast cancer. Breast Cancer Res Treat 2004;84:161-171.
34. Buzdar AU, Kau SW, Smith TL et al. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 1993;71:3680-3684.
35. Benchalal M, Le Prise E, de Lafontan E et al. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group. Cancer 2005; 104:240-250.
36. Metz JM, Schultz DJ, FoxKet al. Analysis ofoutcomes for high-risk breast cancer based on interval from surgery to postmastectomy radiation therapy. Cancer J 2000;6:324-330.
37. Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane Database Syst Rev 2006; 4:CD005212.
38. Bellon JR, Come SE, Gelman RS et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:1934-1940.
39. Povoski SP, Jimenez RE, Wang WP et al. Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer. BMC Cancer 2009;9:254.
40. Lohrisch C, Paltiel C, Gelmon K et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006;24:4888-4894.
41. Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol 2003;21:3792-3797.
42. Cold S, Düring M, Ewertz M et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG).BrJ Cancer 2005;93:627-632.
43. Rouëssé J, dela Lande B, Bertheault-Cvitkovic F et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys 2006;64: 1072-1080.
44. Haffty BG, Kim JH, Yang Q et al. Concurrent chemoradiation in the conservative management of breast cancer. Int J Radiat Oncol Biol Phys 2006; 66:1306-1312.
45. Toledano A, Azria D, Garaud P et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol 2007; 25:405-410.
46. Ismaili N, Mellas N, Masbah O et al. Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol 2009;4:12.
47. Gelber RD, Gelber S; International Breast Cancer Study Group; Breast International Group. Facilitating consensus by examining patterns of treatment effects. Breast 2009;18(suppl 3):S2-S8.
48. Ng W, Delaney GP, Jacob S et al. Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer 2010;46:703-712.
49. Bickell NA, Weidmann J, Fei K et al. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol 2009;27:5160-5167.
50. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
51. Albain KS, Barlow WE, Ravdin PM et al. Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in post-menopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374: 2055-2063.
52. Pritchard KI. Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 2008;112(3 suppl):718-722.
53. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4:459-471.
54. Pritchard KI, Paterson AH, Fine S et al. Randomized trial of cyclophosph-amide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 1997;15:2302-2311.
55. Sertoli MR, Pronzato P, Ventorini M et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer [abstract]. Proc Am Soc Clin Oncol 2002;21:46a.
56. Pico C, Martin M, Jara C, et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004;15:79-87.
57. Chargari C, Toillon RA, Macdermed D et al. Concurrent hormone and ra-diation therapy in patients with breast cancer: what is the rationale? Lancet Oncol 2009;10:53-60.
58. Ramóny Cajal T, Altés A, Paré L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010;119:33-38.
59. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 2009;9:824-833.
60. Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009;45: 1909-1915.
61. Rossi E, Morabito A, Di Rella F et al. Endocrine effects of adjuvant letro-zole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009;27: 3192-3197.
62. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360: 679-691.
63. Mauri D, Valachis A, Polyzos NP et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010;8: 279-286.
64. Ahn PH, Vu HT, Lannin D et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005;23:17-23.
65. Harris EE, Christensen VJ, Hwang WT et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005;23:11-16.
66. Pierce LJ, Hutchins LF, Green SR et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 2005;23:24-29.
67. Bentzen S, Skoczylas J, Overgaard M et al. Radiotherapy-related lung fi-brosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88:918-922.
68. Fowble B, Fein DA, Hanlon AL et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 1996;35: 669-677.
69. Wazer D, DiPetrillo T, Schmidt-Ulrich R et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1992;10:356-363.
70. Azria D, Gourgou S, Sozzi WJ et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 2004;91:1251-1260.
71. Azria D, Larbouret C, Cunat S et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 2005;7:R156-R163.
72. Azria D, Belkacemi Y, Romieu G et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010;11: 258-265.
73. Recht A. Radiotherapy, antihormonal therapy, and personalised medicine. Lancet Oncol 2010;11:215-216.
74. Ishitobi M, Komoike Y, Motomura K et al. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer. Anticancer Res 2009;29:4791-4794.
75. Boone JJ, Bhosle J, Tilby MJ et al. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 2009;8:3015-3023.
76. Végran F, Boidot R, Coudert B et al. Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br J Cancer 2009;101:1357-1364.
77. Longo R, D'Andrea M, Sarmiento R et al. Pharmacogenetics in breast cancer: focus onhormone therapy, taxanes, trastuzumab and bevacizumab. Expert Opin Investig Drugs 2010;19:S41-S50.
78. Straehle C, Cardoso F, Azambuja E et al. Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer. Crit Care Med 2009;37:S22-S29.
79. Belkacémi Y, Laharie-Mineur H, Gligorov J et al. Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer. Cancer Radiother 2007;11:266-275.
80. Colozza M, deAzambuja E, Cardoso F, et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. The Oncologist 2006; 11:111-125.
81. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(1 Suppl 3):13-19.
82. Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Hercep-tin). Semin Oncol 2001;28(1 Suppl 3):1-12.
83. Pietras RJ, Poen JC, Gallardo D et al. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of breast cancer cells overexpressing this oncogene. Cancer Res 1999;59:1347-1355.
84. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005;353: 1673-1684.
85. Harris EE, Correa C, Hwang WT,et al, Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006;24:4100-4106.
86. Cuzick J, Stewart H, Rutqvist L et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994;12:447-453.
87. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
88. Rastogi P, Jeong J, Geyer CE et al. Five year update of cardiac dysfunction on NSABP B-31:Arandomized trialof AC3paclitaxel vs. AC3paclitaxel with trastuzumab in HER2 positive, node positive operable breast cancer [Abstract]. Proc Am Soc Clin Oncol 2007;25:6s.
89. Tan-Chiu E, Yothers G, Romond E, etal. Assessment ofcardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
90. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxo-rubicin and cyclophosphamide followed by paclitaxel with or without tras-tuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008;26:1231-1238.
91. Slamon DJ, Eiermann W, Robert N et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: Second interim efficacy analysis [Abstract]. Breast Cancer Res Treat 2006;100:S63(52a).
92. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
93. Belkacémi Y, Gligorov J, Ozsahin M et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute tox-icity analyses from the French multicentric study. Ann Oncol 2008;19: 1110-1116.
94. Kirova YM, Caussa L, Granger B et al. [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy]. Cancer Radiother 2009;13:276-280.
95. Halyard MY, Pisansky TM, Dueck AC et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.JClin Oncol 2009;27:2638-2644.
96. Shaffer R, Tyldesley S, Rolles M et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009;90:122-126.
97. Horton JK, Halle J, Ferraro M et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastu-zumab: a phase II trial. Int J Radiat Oncol Biol Phys 2010;76:998-1004.